Compare Incyte Corporation (INCY) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Oruka Therapeutics Inc. Common Stock — how do they compare? Incyte Corporation trades at $111.75 (market cap $22.63B), while Oruka Therapeutics Inc. Common Stock trades at $76.8 (market cap $5.08B). The key difference: Incyte Corporation is far larger — about 4.5× Oruka Therapeutics Inc. Common Stock's market cap, and Oruka Therapeutics Inc. Common Stock is more actively traded (685,276 versus 1,869,988). Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| INCY | ORKA | |
|---|---|---|
Market Cap | $22.63B | $5.08B |
Volume | 1,869,988 | 685,276 |
Sector | Health | Health |
52-Week High | $129.93 | $113.08 |
52-Week Low | $86.17 | $26.19 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $18.13B | $4.21B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →
